Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celecoxib added to risperidone for acute-phase schizophrenia
IRCT20210831052351N1Phase 3Completed
- Sponsor
- University of Social Welfare and Rehabilitation Sciences
- Start
- Nov 2021
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, double-blind trial of celecoxib in schizophrenia (2 arms), sponsored by University of Social Welfare and Rehabilitation Sciences. Primary endpoints: Positive symptoms of schizophrenia, Negative symptoms of schizophrenia and 1 more. Started Nov 2021; status: completed.
02
Drugs
celecoxib
03
Conditions
schizophrenia
Beyond the preview
Go deeper on IRCT20210831052351N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20210831052351N1.